GABRP is a Promising Prognostic Biomarker and Associated with Immune Cell Infiltration in Lung Squamous Cell Carcinoma

References

• Hoy H, Lynch T, Beck M. Surgical treatment of lung cancer. Crit Care Nurs Clin North Am. 2019;31(3):303–313. doi:10.1016/j.cnc.2019.05.002
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Pan J, Huang Z, Xu Y. m5C RNA methylation regulators predict prognosis and regulate the immune microenvironment in lung squamous cell carcinoma. Front Oncol. 2021;11:657466. doi:10.3389/fonc.2021.657466
   PubMed Web of Science ®Google Scholar
• Sorber L, Zwaenepoel K, Deschoolmeester V, et al. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients. Lung Cancer. 2017;107:100–107. doi:10.1016/j.lungcan.2016.04.026
   PubMed Web of Science ®Google Scholar
• Nooreldeen R, Bach H. Current and future development in lung cancer diagnosis. Int J Mol Sci. 2021;22:16. doi:10.3390/ijms22168661
   Google Scholar
• Miller MW. GABA as a neurotransmitter in gastropod molluscs. Biol Bull. 2019;236(2):144–156. doi:10.1086/701377
   PubMed Web of Science ®Google Scholar
• Jiang SH, Zhu LL, Zhang M, et al. GABRP regulates chemokine signalling, macrophage recruitment and tumour progression in pancreatic cancer through tuning KCNN4-mediated Ca(2+) signalling in a GABA-independent manner. Gut. 2019;68(11):1994–2006. doi:10.1136/gutjnl-2018-317479
   PubMed Web of Science ®Google Scholar
• Chen C, Wu B, Wang M, Chen J, Huang Z, Shi JS. GABRP promotes CD44s-mediated gemcitabine resistance in pancreatic cancer. PeerJ. 2022;10:e12728. doi:10.7717/peerj.12728
   PubMed Web of Science ®Google Scholar
• Sizemore GM, Sizemore ST, Seachrist DD, Keri RA. GABA(A) receptor pi (GABRP) stimulates basal-like breast cancer cell migration through activation of extracellular-regulated kinase 1/2 (ERK1/2). J Biol Chem. 2014;289(35):24102–24113. doi:10.1074/jbc.M114.593582
   PubMed Web of Science ®Google Scholar
• Sung HY, Yang S-D, Ju W, Ahn J-H. Aberrant epigenetic regulation of GABRP associates with aggressive phenotype of ovarian cancer. Exp Mol Med. 2017;49(5):e335. doi:10.1038/emm.2017.62
   PubMedGoogle Scholar
• Yang Y, Ren L, Li S, et al. GABRP is a potential prognostic biomarker and correlated with immune infiltration and tumor microenvironment in pancreatic cancer. Transl Cancer Res. 2022;11(4):649–668. doi:10.21037/tcr-21-2021
   PubMed Web of Science ®Google Scholar
• Yoshihara K, Shahmoradgoli M, Martínez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612. doi:10.1038/ncomms3612
   PubMed Web of Science ®Google Scholar
• Bade BC, Dela Cruz CS. Lung cancer 2020: epidemiology, etiology, and prevention. Clin Chest Med. 2020;41(1):1–24. doi:10.1016/j.ccm.2019.10.001
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389(10066):299–311. doi:10.1016/S0140-6736(16)30958-8
   PubMed Web of Science ®Google Scholar
• Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019;79(18):4557–4566. doi:10.1158/0008-5472.CAN-18-3962
   PubMed Web of Science ®Google Scholar
• Wang JJ, Lei KF, Han F. Tumor microenvironment: recent advances in various cancer treatments. Eur Rev Med Pharmacol Sci. 2018;22(12):3855–3864. doi:10.26355/eurrev_201806_15270
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14(10):1014–1022. doi:10.1038/ni.2703
   PubMed Web of Science ®Google Scholar
• Bremnes RM, Busund LT, Kilvær TL, et al. The role of tumor-infiltrating lymphocytes in development, progression, and prognosis of non-small cell lung cancer. J Thoracic Oncol. 2016;11(6):789–800. doi:10.1016/j.jtho.2016.01.015
   PubMed Web of Science ®Google Scholar
• Wang SS, Liu W, Ly D, Xu H, Qu L, Zhang L. Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer. Cell Mol Immunol. 2019;16(1):6–18. doi:10.1038/s41423-018-0027-x
   PubMed Web of Science ®Google Scholar
• Miotto D, Lo Cascio N, Stendardo M, et al. CD8+ T cells expressing IL-10 are associated with a favourable prognosis in lung cancer. Lung Cancer. 2010;69(3):355–360. doi:10.1016/j.lungcan.2009.12.012
   PubMed Web of Science ®Google Scholar
• Zeng Y, Lv X, Du J. Natural killer cell‑based immunotherapy for lung cancer: challenges and perspectives (Review). Oncol Rep. 2021;46(5). doi:10.3892/or.2021.8183
   Web of Science ®Google Scholar
• Song P, Li W, Guo L, Ying J, Gao S, He J. Identification and validation of a novel signature based on NK cell marker genes to predict prognosis and immunotherapy response in lung adenocarcinoma by integrated analysis of single-cell and bulk RNA-sequencing. Front Immunol. 2022;13:850745. doi:10.3389/fimmu.2022.850745
   PubMed Web of Science ®Google Scholar
• Hwang I, Kim JW, Ylaya K, et al. Tumor-associated macrophage, angiogenesis and lymphangiogenesis markers predict prognosis of non-small cell lung cancer patients. J Transl Med. 2020;18(1):443. doi:10.1186/s12967-020-02618-z
   PubMed Web of Science ®Google Scholar
• Jackute J, Zemaitis M, Pranys D, et al. Distribution of M1 and M2 macrophages in tumor islets and stroma in relation to prognosis of non-small cell lung cancer. BMC Immunol. 2018;19(1):3. doi:10.1186/s12865-018-0241-4
   PubMedGoogle Scholar
• Zhu Y, Zhang X. Investigating the significance of tumor-infiltrating immune cells for the prognosis of lung squamous cell carcinoma. PeerJ. 2019;7:e7918. doi:10.7717/peerj.7918
   PubMed Web of Science ®Google Scholar
• Guo L, Yi J, Liu M, Li J. The prognostic landscape of tumor-infiltrating immune cells in lung squamous cell carcinoma. Ann Translat Med. 2021;9(9):799. doi:10.21037/atm-21-1852
   PubMed Web of Science ®Google Scholar
• Zhou F, Qiao M, Zhou C. The cutting-edge progress of immune-checkpoint blockade in lung cancer. Cell Mol Immunol. 2021;18(2):279–293. doi:10.1038/s41423-020-00577-5
   PubMed Web of Science ®Google Scholar
• Zhang Q, Tang L, Zhou Y, He W, Li W. Immune checkpoint inhibitor-associated pneumonitis in non-small cell lung cancer: current understanding in characteristics, diagnosis, and management. Front Immunol. 2021;12:663986. doi:10.3389/fimmu.2021.663986
   PubMed Web of Science ®Google Scholar